TUESDAY, Feb. 26, 2019 (HealthDay News) -- For people with the deadly skin cancer melanoma, one dose of the drug Keytruda before surgery might stop the cancer in its tracks, according to a groundbreaking new study.
Keytruda (pembrolizumab) is a PD-1 inhibitor, an immunotherapy drug that triggers the body's immune response to attack cancer cells. According to results of this study, the...
WEDNESDAY, Feb. 6, 2019 (HealthDay News) -- Medicare rule changes could trigger a spike in out-of-pocket drug costs for patients with multiple sclerosis (MS).
Due to rules that restrict access and require patients to cover more of the cost, those without low-income subsidies can expect to spend almost $6,900 a year out of pocket for MS medicines, researchers reported.
WEDNESDAY, Aug. 1, 2018 (HealthDay News) -- In a sign that the U.S. opioid epidemic is still not under control, a new report shows that prescriptions for the highly addictive painkillers haven't declined in the last decade.
After peaking in 2012-2013, opioid use and doses leveled off. But doses were still higher in 2017 than in 2007, and opioid use was part...
TUESDAY, Dec. 5, 2017 (HealthDay News) -- Your chances of surviving cancer may depend on the type of insurance you have.
Researchers from the Cancer Prevention Institute of California found significant improvements in survival among cancer patients with private insurance or Medicare, but not among those who have public insurance such as Medicaid, or are uninsured.